Drug intelligence / Profile preview

5-fluorouracil + methotrexate + prednimustine

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination chemotherapy regimen used primarily for advanced breast cancer. The combination includes three anticancer agents: 5-fluorouracil (a pyrimidine analog), methotrexate (a folate antagonist), and prednimustine (an alkylating agent). This regimen has been studied in clinical trials for postmenopausal women with advanced breast cancer, showing effectiveness with modest toxicity compared to regimens containing more toxic agents like cyclophosphamide and doxorubicin. In some studies, tamoxifen was added to this combination.

Other names: PMF

Targets

GR (Glucocorticoid receptor)DNADHFR (Dihydrofolate reductase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on 5-fluorouracil + methotrexate + prednimustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5-fluorouracil + methotrexate + prednimustine.

Explore the full profile